Regeneron Pharmaceuticals, Inc. has initiated the first clinical trial of REGN-COV2, its investigational dual antibody cocktail for the prevention and treatment of COVID-19. The REGN-COV2 clinical program will consist of four separate study populations:   Hospitalized COVID-19 patients Non-hospitalized symptomatic COVID-19 patients Uninfected people in groups that are at high-risk of exposure (such as healthcare workers or first responders) Uninfected people with close exposure ...